The goal of the center is to develop original technologies for customized treatment of cancer based on genome-wide screening as well as genome and epigenome analysis. The center also focuses on prognostic and predictive biomarkers for lung, liver, and gastric cancers by conducting integrative analyses of the NGS genome, transcriptome, and epigenome data.
Research Areas
Development of bioinformatics tools and databases
Genomic characterization of various cancers for prognostic and predictive biomarker discovery
Integrative analysis of the NGS genome, transcriptome, and epigenome in large-scale data sets derived from various cancers
Large-scale screening and identification of cancerrelated genes
Functional validation of candidate target genes and biomarkers for the development of therapeutics and diagnostics
Discovery and characterization of active compounds for anti-cancer, anti-metastasis, and anti-relapse therapy
Enhancer remodeling and microRNA alterations are associated with acquired resistance to ALK inhibitors
Bioinformatic identification of prognostic biomarkers and web-based bioinformatic software development
RNF25 promotes gefitinib resistance in EGFRmutant NSCLC cells by inducing NF-κB- mediated ERK reactivation
DDIAS suppresses TRAIL-mediated apoptosis by inhibiting DISC formation and destabilizing caspase-8 in cancer cells
Understanding how histone H3K4 methylation is promoted by H2B ubiquitylation in a Set1 complexdependent manner
Identification of prognostic and therapeutic molecular subtypes and web-based bioinformatic software development
Selected Publications
Stability of the cancer target DDIAS is regulated by the CHIP/HSP70 pathway in lung cancer cells.
Cell Death Dis. 8(1):e2554.
Mi Sun Won (Corresponding)
The novel hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth.
Cell Death Dis. 8(6):e2843.
Mi Sun Won (Co-corresponding)
DNA methylation : an epigenetic mark of cellular memory.
Exp Mol Med. 49(4):e322.
Mirang Kim (First)
Methyl 3-(3-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)-propanamido)benzoate as a novel and dual malate dehydrogenase (MDH) 1/2 inhibitor targeting cancer metabolism.
